Welcome to our dedicated page for SeaStar Medical Holding SEC filings (Ticker: ICU), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Parsing SeaStar Medical鈥檚 SEC disclosures can feel like running a clinical trial of your own. The company鈥檚 10-K dives deep into extracorporeal immunomodulation science, while 8-Ks detail pivotal FDA feedback and capital raises that affect the ICU ticker overnight. Finding the cash runway, dilution terms, or hyperinflammation trial data in hundreds of pages isn鈥檛 easy.
That鈥檚 why Stock Titan pairs every filing with AI-powered summaries that translate complex biotech jargon into plain English. Want the SeaStar Medical quarterly earnings report 10-Q filing without wading through accounting footnotes? Our algorithm highlights burn rate and R&D spend in seconds. Need to watch SeaStar Medical insider trading Form 4 transactions? AG真人官方-time alerts flag each executive stock move, so you never miss a signal.
Browse every disclosure鈥攆rom the SeaStar Medical annual report 10-K simplified to 8-K clinical milestone updates鈥攁longside concise explanations that answer the questions investors actually ask: how new data may impact FDA timelines, whether fresh capital changes dilution math, or why a director just bought shares. With instant access to:
- Form 4 feeds for SeaStar Medical executive stock transactions Form 4
- AI digests of each 10-Q earnings report and 10-K annual filing
- SeaStar Medical proxy statement executive compensation insights
- SeaStar Medical 8-K material events explained the moment they post to EDGAR
Stop searching, start understanding鈥�SeaStar Medical SEC filings explained simply so you can focus on decisions, not deciphering documents.
SeaStar Medical Holding Corporation is registering the resale of up to 10,917,218 shares of common stock held by selling securityholders, comprised principally of shares issuable upon exercise of multiple private-placement warrants issued in July and August 2025. The company had 27,914,596 shares outstanding as of August 5, 2025 and would have 38,831,814 shares outstanding if all related warrants are exercised. SeaStar is a commercial-stage medical device company whose Selective Cytopheretic Device (SCD) received FDA Humanitarian Device Exemption approval for pediatric acute kidney injury on February 21, 2024 and shipped its first commercial pediatric SCD in July 2024. The SCD has received Breakthrough Device Designation for six indications and is in a pivotal adult AKI trial. Financially, the company reported an accumulated deficit of $143.3 million and negative working capital of $0.2 million as of March 31, 2025, and its auditors noted substantial doubt about its ability to continue as a going concern. Recent financings include registered direct offerings and concurrent warrant placements in July and August 2025. Nasdaq has previously issued compliance notices and the company currently faces a minimum bid price deficiency notice with a cure period to January 27, 2026.
SeaStar Medical Holding Corporation disclosed it has resumed an at-the-market equity offering after suspending sales on July 10, 2025. The company previously sold an aggregate of $6.8 million of common stock under the ATM program and had earlier terminated the continuous offering tied to an initial aggregate offering price of $25,000,000. As of August 8, 2025, SeaStar will resume sales under the Company鈥檚 effective Form S-3 for an additional aggregate offering price of $2,166,305. Proceeds, if any, will be used for general corporate purposes, and there is no minimum offering amount so total shares and proceeds are not determinable. Legal opinion and related exhibits are filed with the report.
SeaStar Medical Holding Corporation filed a prospectus supplement to sell up to $2,160,113 of common stock through an at-the-market program with H.C. Wainwright, which will receive a 3.0% commission on sales. The company emphasizes its FDA pediatric Humanitarian Device Exemption approval (received February 21, 2024) and shipment of its first commercial pediatric SCD in July 2024, plus multiple FDA Breakthrough Device Designations and an ongoing pivotal adult AKI trial.
The filing discloses material financial and listing risks: an auditor’s going-concern emphasis, positive working capital of $2.6 million as of June 30, 2025 but recurring losses, large warrant and potential dilution overhang (tens of millions of shares issuable), and a Nasdaq notice for failing the $1.00 minimum bid price with 180 days to cure (notice dated July 31, 2025). The company also implemented indefinite 20% reductions to certain executive salaries and director fees to conserve cash.
SeaStar Medical Holding Corporation is registering 1,500,000 shares of its common stock for issuance under the Amended and Restated 2022 Omnibus Incentive Plan, reflecting a shareholder-approved amendment to that plan. The registration also covers any additional shares issuable under Rule 416 for stock dividends, splits or similar adjustments. The filing incorporates prior S-8 registrations for the same plan (listing 50,800, 47,200 and 472,456 shares after giving effect to a 1-for-25 reverse stock split) and notes the reverse split that adjusted share amounts.
The document incorporates the company鈥檚 recent annual and quarterly reports by reference, includes an exhibit index identifying the amended plan as Exhibit 99.1, and is signed by the CEO and other officers and directors, with a standard power of attorney for amendments. The filing itself does not disclose the company鈥檚 total outstanding shares or provide financial performance data.
FAQ
What is the current stock price of SeaStar Medical Holding (ICU)?
What is the market cap of SeaStar Medical Holding (ICU)?
